ApobiologixApobiologix, a division of Apotex Inc., focuses on the commercialization of biosimilars. In Canada, Apobiologix has led the way in establishing a robust biosimilar presence through its filgrastim portfolio – Grastofil and Lapelga. Apobiologix is committed to transforming access to affordable therapies in oncology and beyond through innovation, development, and partnerships. The Apobiologix Partnership Program (APP), launched in 2020, is an initiative focused on supporting our partners with a variety of important projects and programs that are meaningful to them. We work in cooperation with our HCP partners to enhance patient access, optimize patient care and ensure sustainability of our healthcare system. Our biosimilar program is providing affordable, advanced, and high-quality solutions for patients through our ANSWERS – Patients Support Program. For more information, please visit http://www.apobiologix.com.